



FRIDAY, DECEMBER 4, 2009

The Westin Diplomat • Great Hall 3 • Hollywood, Florida

12:20 PM – 12:30 PM Luncheon Seating

12:30 PM – 1:50 PM Scientific Program

Please join us for a Friday luncheon symposium

Progress in IBD Therapy: Achieving Current and Future Therapeutic Goals

PROGRAM FACULTY

Stephen B. Hanauer, MD—Program Chair

University of Chicago Pritzker School of Medicine
Chicago, Illinois

Asher Kornbluth, MD

Mount Sinai School of Medicine
New York, New York

Scott E. Plevy, MD

University of North Carolina School of Medicine
Chapel Hill, North Carolina

Daniel H. Present, MD

Mount Sinai School of Medicine
New York, New York

William J. Sandborn, MD

Mayo Clinic
Rochester, Minnesota

Co-sponsored by  **Curatio** 
CME Institute

This activity is supported by independent educational grants from
Therakos, Inc. and Warner Chilcott.

*A satellite symposium held in conjunction with the 2009 Advances in Inflammatory
Bowel Diseases Crohn's & Colitis Foundation's Clinical & Research Conference.*

There is no need to preregister for this meeting. Seating is limited and will be available on a first-come, first-served basis; to ensure seating, we recommend that you arrive at the luncheon symposium early.

PROGRAM OVERVIEW

Inflammatory bowel disease (IBD) research and development continues to be a dynamic area. New data are refining our understanding of how to use foundational therapies, and new biologics are joining the therapeutic armamentarium. Given the constantly changing landscape of IBD research, it is essential that clinicians stay current on how these data relate to achieving both current and evolving therapeutic goals in their IBD patients. This program highlights current information of high relevance to gastroenterologists in their daily care of patients with IBD. The faculty members review current research and use clinical experience from their own practices in interactive panel discussions on the optimal treatment strategies for ulcerative colitis and Crohn's disease.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with IBD.

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

- Compare current therapeutic end points for treatment of ulcerative colitis and Crohn's disease
- Identify gaps in the current therapeutic end points and the rationale for evolving therapeutic goals
- Design effective treatment plans that incorporate knowledge of the efficacy of various therapeutic agents to achieve individual therapeutic end points
- Discuss future trends in patient classification and potential therapeutic targets

ACCREDITATION STATEMENT

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The University of Chicago Pritzker School of Medicine designates this educational activity for a maximum of 1.25 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The University of Chicago Pritzker School of Medicine and Curatio CME Institute adhere to the ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control the content of this educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.